NRx Pharmaceuticals, Inc.

For the 6 months ended June 30, 2026, NRx reported a net loss of $18 million versus a net loss of $23.1 million in the comparable period of 2025. Net operating loss was $11.3 million versus $7.6 million a year ago, mainly due to higher R&D and SG&A tied to the anticipated near-term commercial launch of preservative-free ketamine. Cash and cash equivalents were $26.7 million at June 30, 2026 versus $7.8 million at December 31, 2025, helped by a public offering with gross proceeds of more than $22 million. Management said current cash resources, the economic potential of the pending ANDA launch, anticipated clinic revenue growth, and use of the ATM facility should support operations for at least a year. Forward-looking targets included aiming for 2026 approval for preservative-free ketamine, aiming for 2027 approval for NRX-100, and a first-in-human ALS trial for GNK-301 targeted for July 2027.

Jonathan Javitt framed the quarter as a company-wide inflection point, citing progress across ketamine, NRX-100, NRX-101, HOPE Therapeutics, and GeNeuro. He emphasized that the ketamine ANDA has only one major remaining deficiency, that NRX-100 is being advanced with real-world-evidence support from Washington, and that SPARC-TMS could materially broaden NRX-101’s market if the DARPA-backed trial succeeds. His tone was highly optimistic and expansive, with repeated references to potential military, first responder, and broader population use.

Michael Abrams focused on the financial improvement and runway. He reported a 6-month net loss of $18 million versus $23.1 million year over year, and a net operating loss of $11.3 million versus $7.6 million, with the increase driven by R&D and SG&A ahead of a possible ketamine launch. He also highlighted cash of $26.7 million at June 30, 2026, up from $7.8 million at year-end 2025, largely from a public offering with gross proceeds of more than $22 million, and said the company expects at least a year of operating support from cash, launch potential, clinic revenue, and the ATM facility.

Analysts focused on whether KETAFREE and the ketamine NDA would overlap competitively, and management said they are legally different drugs with different NDCs and different commercial pathways; only the NDA product would carry a depression label, while KETAFREE would not. On SPARC-TMS, management said DARPA is funding research rather than deciding indications, and that the company may pursue both bipolar depression and the broader treatment-resistant depression opportunity depending on resources and shareholder input. On GeNeuro/GNK-301, management said it expects to use nondilutive funding sources, pointing to NIH, congressional ALS programs, and defense appropriations rather than relying mainly on NRx capital.